prednisone has been researched along with Angiogenesis, Pathologic in 19 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neovascularisation and bone resorption are related to myeloma disease activity." | 1.32 | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. ( Angelopoulou, MK; Dimopoulou, MN; Gribabis, DA; Kokoris, SI; Kyrtsonis, MC; Pangalis, GA; Siakantaris, MP; Vassilakopoulos, TP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Brito, ABC | 1 |
| Delamain, MT | 1 |
| Fanelli, MF | 1 |
| Soares, FA | 1 |
| de Souza, CA | 1 |
| Vassallo, J | 1 |
| Lima, CSP | 1 |
| Butler, MJ | 1 |
| Aguiar, RCT | 1 |
| Kokonozaki, M | 1 |
| Tsirakis, G | 1 |
| Devetzoglou, M | 1 |
| Kyriakaki, S | 1 |
| Antonakis, A | 1 |
| Vyzoukaki, R | 1 |
| Pappa, CA | 1 |
| Tzardi, M | 1 |
| Alexandrakis, MG | 1 |
| Lenz, G | 1 |
| Wright, G | 1 |
| Dave, SS | 1 |
| Xiao, W | 1 |
| Powell, J | 2 |
| Zhao, H | 1 |
| Xu, W | 1 |
| Tan, B | 1 |
| Goldschmidt, N | 1 |
| Iqbal, J | 1 |
| Vose, J | 1 |
| Bast, M | 1 |
| Fu, K | 1 |
| Weisenburger, DD | 1 |
| Greiner, TC | 1 |
| Armitage, JO | 1 |
| Kyle, A | 1 |
| May, L | 1 |
| Gascoyne, RD | 1 |
| Connors, JM | 1 |
| Troen, G | 1 |
| Holte, H | 1 |
| Kvaloy, S | 1 |
| Dierickx, D | 1 |
| Verhoef, G | 1 |
| Delabie, J | 1 |
| Smeland, EB | 1 |
| Jares, P | 1 |
| Martinez, A | 1 |
| Lopez-Guillermo, A | 1 |
| Montserrat, E | 1 |
| Campo, E | 1 |
| Braziel, RM | 1 |
| Miller, TP | 1 |
| Rimsza, LM | 1 |
| Cook, JR | 1 |
| Pohlman, B | 1 |
| Sweetenham, J | 1 |
| Tubbs, RR | 1 |
| Fisher, RI | 1 |
| Hartmann, E | 1 |
| Rosenwald, A | 1 |
| Ott, G | 1 |
| Muller-Hermelink, HK | 1 |
| Wrench, D | 1 |
| Lister, TA | 1 |
| Jaffe, ES | 1 |
| Wilson, WH | 1 |
| Chan, WC | 1 |
| Staudt, LM | 1 |
| Kluetz, PG | 1 |
| Figg, WD | 1 |
| Dahut, WL | 1 |
| Ruan, J | 1 |
| Martin, P | 1 |
| Coleman, M | 1 |
| Furman, RR | 1 |
| Cheung, K | 1 |
| Faye, A | 1 |
| Elstrom, R | 1 |
| Lachs, M | 1 |
| Hajjar, KA | 1 |
| Leonard, JP | 1 |
| Petrylak, DP | 1 |
| Rujirojindakul, P | 1 |
| Lekhakula, A | 1 |
| Tanaka, K | 1 |
| Watanabe, M | 1 |
| Kuraishi, Y | 1 |
| Kimura, I | 1 |
| Suzuki, T | 1 |
| Kiniwa, M | 1 |
| Kyrtsonis, MC | 1 |
| Vassilakopoulos, TP | 1 |
| Siakantaris, MP | 1 |
| Kokoris, SI | 1 |
| Gribabis, DA | 1 |
| Dimopoulou, MN | 1 |
| Angelopoulou, MK | 1 |
| Pangalis, GA | 1 |
| Ganjoo, KN | 1 |
| An, CS | 1 |
| Robertson, MJ | 1 |
| Gordon, LI | 1 |
| Sen, JA | 1 |
| Weisenbach, J | 1 |
| Li, S | 1 |
| Weller, EA | 1 |
| Orazi, A | 1 |
| Horning, SJ | 1 |
| Handa, H | 1 |
| Irisawa, H | 1 |
| Komatsumoto, S | 1 |
| Matsushima, T | 1 |
| Tsukamoto, N | 1 |
| Nojima, Y | 1 |
| Murakami, H | 1 |
| Kelly, PJ | 1 |
| Weiter, JJ | 1 |
| Doxanas, MT | 1 |
| Kelley, JS | 1 |
| Prout, TE | 1 |
| Mayer, J | 1 |
| Brouillette, G | 1 |
| Corriveau, LA | 1 |
| Ho, AC | 1 |
| Maguire, AM | 1 |
| Yannuzzi, LA | 1 |
| Fishere, YL | 1 |
| Galetta, SL | 1 |
| Sergott, RC | 1 |
| Kleiner, RC | 1 |
| Najarian, LV | 1 |
| Schatten, S | 1 |
| Jabs, DA | 1 |
| Patz, A | 1 |
| Kaplan, HJ | 1 |
| Mitchell, DJ | 1 |
| Steahly, LP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma[NCT00151281] | Phase 2 | 25 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Stromal angiogenesis was assessed using blood vascular and perivascular markers, including VEGFR-1, VEGFR-2, CD34, and a-SMA, as well as lymphatic vascular markers ofVEGFR-3, podoplanin, and Lyve-1. (NCT00151281)
Timeframe: 38 months
| Intervention | pg/mL (Median) |
|---|---|
| RT-PEPC Drug Therapy | 109.5 |
measured by overall Response Rate (ORR), which includes Complete response and partial response. (NCT00151281)
Timeframe: 38 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment Arm | 73 |
Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. (NCT00151281)
Timeframe: 38 months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 or 4 neutropenia | Anemia | Thrombocytopenia | Fatigue | Constipation | Cough | Nausea | Neuropathy | Dyspnea | Rash | |
| RT-PEPC Drug Therapy | 14 | 1 | 4 | 22 | 14 | 14 | 13 | 13 | 11 | 10 |
"QoL assessments were obtained with version 3 of the Functional Assessment of Cancer Therapy-General (FACT-G) instrument. The FACT-G is comprised of four subscales: physical well-being (7-items, score range 0-28), social/family well-being (7-items, score range 0-28), emotional well-being (6-items, score range 0-24), and functional well-being (7-items, score range 0-28). Users of the FACT-G are able to generate an overall score and four subscale scores with ranges and distributions that are sample-specific. All questions in the FACT-G use a 5-point rating scale (0 = Not at all to 4 = Very much) A higher number indicates a better Quality of Life, and has a possible range of 0-108 points.~ANOVA was used to compare the difference in the means of total score among the different time points (baseline, every 2M until 6M, and every 6M until PD). The mean of the total FACT-G scores at baseline and mean of total score at all timepoints (using ANOVA) are reported below." (NCT00151281)
Timeframe: baseline, every 2 months until Month 6, and every 6 months until disease progression
| Intervention | FACT-G score (Mean) | |
|---|---|---|
| Mean FACT-G Score at baseline | Mean Total FACT-G Score between all time points | |
| RT-PEPC Drug Therapy | 83.3 | 89.4 |
4 reviews available for prednisone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Angiogenesis inhibitors in the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pro | 2011 |
Update on hemangiomas and vascular malformations.
Topics: Child; Congenital Abnormalities; Female; Glucocorticoids; Hemangioma; Humans; Laser Therapy; Male; N | 1999 |
3 trials available for prednisone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Combined Chemotherap | 2012 |
Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2006 |
12 other studies available for prednisone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2021 |
Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 2015 |
Stromal gene signatures in large-B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Peroral TAS-202 reduced vessel density in rats with adjuvant-induced arthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Blood Vessels; Dep | 2003 |
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2004 |
[Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Drug Administrati | 2006 |
Resolution of optic disk neovascularization associated with intraocular inflammation.
Topics: Adult; Child; Dexamethasone; Female; Humans; Middle Aged; Neovascularization, Pathologic; Ophthalmic | 1980 |
Sarcoidosis with neovascularization of the optic nerve head.
Topics: Adult; Eye Diseases; Hemorrhage; Humans; Male; Neovascularization, Pathologic; Optic Disk; Optic Ner | 1980 |
[Sarcoidosis and rubeosis iridis].
Topics: Adult; Humans; Iris; Male; Neovascularization, Pathologic; Ocular Hypertension; Prednisone; Sarcoido | 1983 |
Rapidly progressive optic disk neovascularization after diabetic papillopathy.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female | 1995 |
Vaso-occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy).
Topics: Adult; Blood Coagulation Factors; Cardiolipins; Enzyme-Linked Immunosorbent Assay; Fluorescein Angio | 1989 |
Pseudotumor cerebri and macular disease.
Topics: Adult; Choroid; Diplopia; Female; Fundus Oculi; Headache; Humans; Intraocular Pressure; Macular Edem | 1989 |